Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Mounjaro Label Updated with PIII CV Data Showing Noninferiority
September 16, 2026
-
BUSINESS Moderna Ratchets Up Oncology Drive with Cancer Vaccine PIII Win
September 15, 2026
-
BUSINESS Taiho Takes Small-Molecule Expertise into ADCs; 3-Payload IND Due This Year
September 14, 2026
-
REGULATORY Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
-
BUSINESS Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
-
BUSINESS Takeda R&D Chief Plump to Retire in June 2027
September 11, 2026
-
BUSINESS Ex-Takeda CEO Weber Joins Rakuten Medical as Vice Chairman
September 10, 2026
-
REGULATORY MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
-
REGULATORY Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
-
BUSINESS 3 Chugai Researchers Win Lasker Award for Hemlibra Discovery
September 10, 2026
-
BUSINESS Medipal Names Imagawa as New CEO in 1st Leadership Change in 14 Years
September 9, 2026
-
REGULATORY PMDA Generic GMP Inspections a Real-World Test to Stem Startup Risks: Official
September 8, 2026
-
REGULATORY CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
September 8, 2026
-
COMMENTARY As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
September 7, 2026
-
REGULATORY LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
September 4, 2026
-
BUSINESS Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
-
REGULATORY Japan to Revisit Handling of Steroid Creams under OTC-Like Drug Charge
September 4, 2026
-
ACADEMIA Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
-
REGULATORY New MHLW Pharma Chief Puts AI in Regulatory Reviews High on Agenda
September 3, 2026
-
REGULATORY MHLW Lines Up 32.6 Billion Yen for 4 New Drug Discovery Support Projects
September 2, 2026
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…